-
1Academic Journal
المؤلفون: T. H. Nguyen, L. Yu. Ilchenko, L. I. Melnikova, K. K. Kyuregyan, I. V. Gordeychuk, Т. Х. Нгуен, Л. Ю. Ильченко, Л. И. Мельникова, К. К. Кюрегян, И. В. Гордейчук
المصدر: The Russian Archives of Internal Medicine; Том 14, № 2 (2024); 124-131 ; Архивъ внутренней медицины; Том 14, № 2 (2024); 124-131 ; 2411-6564 ; 2226-6704
مصطلحات موضوعية: фиброз печени, nucleoside and nucleotide analogs, efficacy, liver fibrosis, аналоги нуклеоз(т)идов, эффективность
وصف الملف: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1751/1307; World Health Organization. Hepatitis B Fact Sheet [Electronic resource]. URL: https://www.who.int/news-room/factsheets/detail/hepatitis-b. (date of the application: 18.07.2023); World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240027077. (date of the application: 15.01.2024); О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году. Государственный доклад. М, Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2023; 368 с.; EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology. 2017; 67(2): 370-398. DOI:10.1016/j.jhep.2017.03.021.; Terrault N.A., Lok A.S., McMahon B.J., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4): 1560-1599. DOI:10.1002/hep.29800.; Знойко О.О., Климова Е.А., Малинникова Е.Ю. и др. Хронический вирусный гепатит B (ХВГВ) у взрослых. Клинические рекомендации. М, Министерство здравоохранения Российской Федерации. 2019; 70 с.; Yim H., Kim I., Suh S., et al. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. Journal of Viral Hepatitis. 2018; 25(11): 1321-1330. DOI:10.1111/jvh.12934.; Cho J.-Y., Sohn W., Sinn D.-H., et al. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. The Korean journal of internal medicine. 2017; 32(4): 636-646. DOI:10.3904/kjim.2016.096.; Suzuki F., Hosaka T., Suzuki Y., et al. Long-term outcome of entecavir treatment of nucleos (t) ide analogue-naïve chronic hepatitis B patients in Japan. Journal of Gastroenterology. 2019; 54(2): 182-193. DOI:10.1007/s00535-018-1502-y.; Ибрагимов Э.К., Абдурахманов Д.Т., Розина Т.П. и др. Эффективность и безопасность длительной терапии хронического гепатита В нуклеозидными и нуклеотидными аналогами. Терапевтический архив. 2019; 91(2): 40-47. DOI:10.26442/00403660.2019.02.000073.; Jacobson I.M., Washington M.K., Buti M., et al. Factors associated with persistent increase in level of alanine aminotransferase in patients with chronic hepatitis B receiving oral antiviral therapy. Clinical Gastroenterology and Hepatology. 2017; 15(7): 1087-1094. e1082. DOI:10.1016/j.cgh.2017.01.032.; Huikun Z., Jiang J., Minghua S., et al. Efficacy of entecavir versus tenofovir disoproxil fumarate in treatment of chronic hepatitis B patients with high viral load. Journal of Clinical Hepatology. 2022; 38(3): 532-536. DOI:10.3969/j.issn.1001-5256.2022.03.008.; Sun J., Li Y., Sun X., et al. Dynamic Changes of the Aspartate Aminotransferase-to-Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment. Journal of Ultrasound in Medicine. 2019; 38(6): 1441-1448. DOI:10.1002/jum.14822.; Xu W., Hu Q., Chen C., et al. Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study. Infectious Diseases and Therapy. 2022; 12(2): 487-498. DOI:10.1007/s40121-022-00738-1.; World Health Organization. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection [Electronic resource]. URL: https://www.who.int/publications/i/item/9789241549059. (date of the application: 11.01.2024); https://www.medarhive.ru/jour/article/view/1751
-
2Academic Journal
المؤلفون: A. D. Nikogosova, D. V. Umrik, O. M. Tsirulnikova, А. Д. Никогосова, Д. В. Умрик, О. М. Цирульникова
المصدر: Russian Journal of Transplantology and Artificial Organs; Том 24, № 3 (2022); 37-41 ; Вестник трансплантологии и искусственных органов; Том 24, № 3 (2022); 37-41 ; 2412-6160 ; 1995-1191
مصطلحات موضوعية: иммуноглобулин, liver transplantation, nucleos(t)ide analogues, entecavir, tenofovir, immunoglobulin, трансплантация печени, аналоги нуклеоз(т)идов, энтекавир, тенофовир
وصف الملف: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/1512/1328; Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl. 2002; 8 (10): 892– 900.; Nugroho A, Lee KW, Kim H, Yi NJ, Suh KS. De novo Hepatitis B Virus Infection After Liver Transplantation in Hepatitis B Core-positive Recipients Using Hepatitis B Core-negative Grafts. Transplant Proc. 2019; 51 (3): 842–844.; Verna EC. Updated Hepatitis B Guidance: Implications for liver transplant patients. Liver Transplant. 2018; 24 (4): 465–469.; Jung H-S, Choi Y, Yoon KC, Hong SY, Suh S, Hong K et al. Hepatitis B immunoglobulin prophylaxis for de novo hepatitis B infection in liver transplantation: a 30- year experience. Ann Transl Med. 2022; 10 (5): 243.; Wang SH, Loh PY, Lin TL, Lin LM, Li WF, Lin YH et al. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft. Liver Transpl. 2017; 23 (10): 1266–1272.; Hornuss D, Rudi A, Koerner L, Mohr I, Merle U, Wehling C et al. HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive livergrafts to HBV-naïve recipients: A retrospective study. Clin Res Hepatol Gastroenterol. 2021; 45 (2): 101496.; Riveiro-Barciela M. Outcome and risk of de novo Hepatitis B after liver transplantation: Are all anti-HBc-positive grafts the same? Clin Res Hepatol Gastroenterol. 2020; 44 (6): 791–793.; Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67 (4): 1560–1599.; Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: A systematic review. J Hepatol. 2010; 52 (2): 272–279.; Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46 (1): 254–265.; Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012; 56 (Suppl 1): S112–S122.; Katz LH, Tur-Kaspa R, Guy DG, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane database Syst Rev. 2010. 7 (7): CD006005.; Wong TC, Fung JY, Cui TY, Lam AH, Dai JW,https://journal.transpl.ru/vtio/editor/submissionEngCit/1512 Chan AC et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis. J Hepatol. 2019; 70 (6): 1114–1122.; Ossami Saidy RR, Eurich F, Postel MP, Dobrindt EM, Feldkamp J, Schaper SJ et al. Clinical and Histological Long-Term Follow-Up of De novo HBV-Infection after Liver Transplantation. Medicina (Kaunas). 2021; 57 (8): 767.; https://journal.transpl.ru/vtio/article/view/1512
-
3Academic Journal
المؤلفون: A. D. Nikogosova, D. V. Umrik, O. M. Tsirulnikova, А. Д. Никогосова, Д. В. Умрик, О. М. Цирульникова
المصدر: Russian Journal of Transplantology and Artificial Organs; Том 24, № 2 (2022); 31-38 ; Вестник трансплантологии и искусственных органов; Том 24, № 2 (2022); 31-38 ; 2412-6160 ; 1995-1191
مصطلحات موضوعية: тенофовир, de novo, liver transplantation, nucleos(t)ide analogues, entecavir, tenofovir, трансплантация печени, аналоги нуклеоз(т)идов, энтекавир
وصف الملف: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/1492/1307; Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol. 2007; 13 (1): 14–21.; Jiang Y et al. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell carcinoma. 2021; 8: 435–450.; Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009; 19 (4): 231–234.; Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017; 31 (3): 249–255.; Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol. 2019 Aug; 10: 2048.; Chen HY et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019; 68 (3): 512–521.; Terrault NA et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63 (1): 261–283.; Vodkin I, Kuo A. Extended Criteria Donors in Liver Transplantation. Clin Liver Dis. 2017; 21 (2): 289–301.; Castells L et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl. 2002; 8 (10): 892–900.; Devarbhavi HC et al. Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype. Liver Transpl. 2002; 8 (6): 550–555.; Marzano A et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005; 11 (4): 402–409.; Roche B, Samuel D. Withdrawal of posttransplant hepatitis B virus prophylaxis: A blind test. Liver Transpl. 2016; 22 (9): 1183–1185.; Faria LC et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008; 134(7): 1890–1899.; Rehermann B et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996; 2 (10): 1104–1108.; Werle-Lapostolle B et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004; 126 (7): 1750–1758.; Sung JJY et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005; 128 (7): 1890–1897.; Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006; 1: 23–61.; Löwenberg M et al. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med. 2007; 13 (4): 158–163.; Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013; 191(12): 5785–5791.; Shu-Sen Zheng et al. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int. 2002; 1 (3): 327–329.; Adam R et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int. 2018; 31 (12): 1293–1317.; Li MS et al. The strategy and efficacy of prophylaxis against hepatitis B virus recurrence after liver transplantation for HBV-related diseases in the era of potent nucleos(t)ide analogues: A meta-analysis. J Dig Dis. 2021; 22 (2): 91–101.; Saidy RRO et al. Clinical and Histological Long-Term Follow-Up of De Novo HBV-Infection after Liver Transplantation. Medicina (Kaunas). 2021; 57 (8): 767.; Adil B et al. Hepatitis B Virus and Hepatitis D Virus Recurrence in Patients Undergoing Liver Transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus. Transplant Proc. 2016; 48 (6): 2119–2123.; Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006; 65 (8): 983–989.; Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015; 313 (16): 1617–1618.; Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50 (3): 661–662.; O’Grady JG et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992; 14 (1): 104–111.; Davies SE et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991; 13 (1): 150–157.; Harrison RF et al. Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis. Histopathology. 1993; 23 (1): 21–28.; Belle SH, Beringer KC, Detre KM. Trends in liver transplantation in the United States. Clin Transpl. 1993; 19: 35.; Crippin J et al. Retransplantation in hepatitis B – a multicenter experience. Transplantation. 1994; 57 (6): 823–826.; Van Thiel DH et al. Medical aspects of liver transplantation. Hepatology. 1984; 4 (1 Suppl): 79S–83S.; Lauchart W, Müller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc. 1987; 19(5): 4051–4053.; Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis. 2013; 56 (11): 1629–1636.; Terrault NA et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg. 1996; 2 (2): 132–138.; Crespo G et al. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142 (6): 1373–1383.e1.; Karasu Z et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther. 2004; 9 (6): 921–927.; Takaki A, Yagi T, Yamamoto K. Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res. 2015; 45 (1): 38–47.; Wang P et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One. 2014; 9 (8): e104480.; Fung J et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013; 108 (6): 942–948.; Готье СВ и др. Опыт 100 трансплантаций трупной печени в одном центре. Вестник трансплантологии и искусственных органов. 2012; 14 (1): 6–14.; Маломуж ОИ, Чеклецова ЕВ, Хизроев ХМ, Пец ВА, Фокин СВ, Таранов ВА и др. HBV-инфекция de novo у пациентов после ортотопической трансплантации печени: клиническая и вирусологическая характеристика пациентов, оценка эффективности противовирусной терапии. Вестник трансплантологии и искусственных органов. 2012; 14 (3): 24–30.; Цирульникова ОМ, Умрик ДВ, Монахов АР, Зубенко СИ. Профилактика рецидива гепатита В после трансплантации печени: а так ли необходим иммуноглобулин? Вестник трансплантологии и искусственных органов. 2021; 23 (S): 60–61.; Huang KW et al. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virusrelated Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2017; 51 (6): 539–547.; Govan L et al. Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. Eur J Gastroenterol Hepatol. 2015; 27 (8): 882–894.; Chun Yang et al. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol. 2016; 15 (4): 501–511.; Fung J. HBV therapeutic vaccines and cccDNA inhibitors – emergence of a cure. Liver Transpl. 2016; 22 (S1): 52–56.; Bienzle U et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology. 2003; 38 (4): 811–819.; Wang SH et al. Active immunization for prevention of de novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigenpositive graft. Liver Transpl. 2017; 23 (10): 1266–1272.; Chan HLY et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016; 1 (3): 185–195.; Sripongpun P et al. Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clin Gastroenterol Hepatol. 2020; 18 (3): 747–749.; https://journal.transpl.ru/vtio/article/view/1492
-
4Academic Journal
المؤلفون: Elpaeva E.A., Komissarov A.B., Pisareva M.M., Grudinin M.P., Kiselev O.I.
المصدر: Russian Journal of Infection and Immunity; Vol 5, No 3 (2015); 265-272 ; Инфекция и иммунитет; Vol 5, No 3 (2015); 265-272 ; 2313-7398 ; 2220-7619 ; 10.15789/2220-7619-2015-3
مصطلحات موضوعية: hepatitis B virus, real-time PCR, mutations, sequencing, chronic hepatitis B, аnalogues of nucleos(t)ides, вирус гепатита В, ПЦР, мутации, секвенирование, хронический гепатит В, аналоги нуклеоз(т)идов
وصف الملف: application/pdf
-
5Academic Journal
المؤلفون: ЕЛПАЕВА ЕКАТЕРИНА АЛЕКСАНДРОВНА, КОМИССАРОВ А.Б., ПИСАРЕВА М.М., ГРУДИНИН М.П., КИСЕЛЕВ О.И.
وصف الملف: text/html
-
6Academic Journal
المؤلفون: K. V. Zhdanov, K. V. Kozlov, V. S. Sukachev, К. В. Жданов, К. В. Козлов, В. С. Сукачев
المصدر: Journal Infectology; Том 1, № 4 (2009); 23-35 ; Журнал инфектологии; Том 1, № 4 (2009); 23-35 ; 2072-6732 ; 10.22625/2072-6732-2009-1-4
مصطلحات موضوعية: аналоги нуклеоз(т)идов, Interferon, Peginterferon, Nucleos(t)ide analogues, интерферон, пегилированный интерферон
وصف الملف: application/pdf
Relation: https://journal.niidi.ru/jofin/article/view/270/267; Sherlock S. Course of long incubation (virus B) hepatitis / S. Sherlock // Brit. Med. Bull. 1972. – Vol.28. –P. 109–113.; Levene C. Incidence of antibodies against betalipoproteins (Ag system), and the factors influencing isoimmunisation in transfused patients in the U.S.A. and Italy / C. Levene, B.S. Blumberg, A. Vierrucci et al. // Lancet. – 1967. – Vol.2, №7516. – P. 582–585.; Dane D.S. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis / D.S. Dane, C.H. Cameron, M. Briggs // Lancet. – 1970. – Vol.1, №7649. – P. 695–698.; Vilela M.D. Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers /M.D. Vilela, W.A. Siqueira, L.D. Rodriguez et al. // G E N. – 1977. – Vol. 31, №3. –P. 149–155.; Whitley R. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use / R. Whitley, C. Alford, F. Hess et al. // Drugs. – 1980. – Vol. 20, №4. – P. 267–282.; Auer I.O. Therapy of chronic hepatitis (author’s transl) / I.O. Auer // Leber Magen Darm. – 1980. – Vol.10, №5. – P. 251–258.; Sherlock S. Treatment of chronic hepatitis /S. Sherlock // Ann Acad Med Singapore. – 1980 – Vol.9, №2. – P. 185–187.; Hafkin B. Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses / B. Hafkin, R.B. Pollard, M.L. Tiku et al. // Antimicrob Agents Chemother – 1979. – Vol.16, №6. – P. 781–787.; Fattovich G. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B /G. Fattovich, L. Brollo, S. Boscarro et al. // J.Hepatol. – 1989. – Vol.9, №3. – P. 331–337.; Coppens J.P. Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a 10-month follow up study / J.P. Coppens, C. Cornu, E. Lens et al. // Liver. – 1989. – Vol.9, №5. – P. 307–313.; Porres J.C. Different doses of recombinant alpha interferon in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus / J.C. Porres, V. Carreo, I. Mora et al. // Hepatogastroenterology. – 1988. – Vol.35, №6. – P. 300–303.; Brook M.G. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection / M.G. Brook, L. Petrovic, J.A. McDonald et al. // J. Hepatol. – 1989. – Vol.8, №2. – P. 218–225.; Marcellin P. Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study / P. Marcellin, D. Ouzan, F. Degos et al. // Gastroenterol Clin. Biol. – 1987. – Vol.11, №8-9. – P. 568–573.; Di Bisciglie A.M. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B /A.M. Di Bisciglie, T.L. Fong, M.W. Fried et al. // Am J Gastroenterol. – 1993. – Vol.88, №11. – P. 1887–1892.; Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. / F. Tin, A. Liberati, A. Crax et al. // J Hepatol. 1993 Jun;18(2):154–62.; Lok A.S. Treatment of chronic hepatitis B / A.S. Lok //J. Viral. Hepat. – 1994. – Vol.1, №2. – P. 105–124.; Dusheiko G.M. Lamivudine treatment of chronic hepatitis B / G.M. Dusheiko // Rev. Med. Virol. – 1998. –Vol.8 – P. 153–159.; Hong J.H. Current status of anti-HBV chemotherapy /J.H. Hong, Y. Choi, B.K. Chun et al. // Arch Pharm. Res. –1998. – Vol.21, №2. – P. 89–105.; Doong S.L. Inhibition of the replication of hepatitis B virus in vitro by 2’,3’-dideoxy-3’-thiacytidine and related analogues / S.L. Doong, C.H. Tsai, R.F. Schinazi et al. // Proc. Natl. Acad. Sci. U S A. – 1991. – Vol.88, №19. – P. 8495–8499.; Lai C.L. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group / C.L. Lai, R.N. Chien, N.W. Leung et al. // N. Engl. J. Med. – 1998. – Vol.339. – P. 61–68.; Sokal E. Doze finding and safety of lamivudine in children and adolescents with chronic hepatitis B / E. Sokal, E.A. Roberts, G. Mieli-Vergani et al. // Hepatology. – 1998. – Vol.28. – P. 489A.; Grellier L. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis / L. Grellier,D. Mutimer, M. Ahmend et al. // Lancet. - 1996. – Vol.348. – P. 1212–1215.; Perrilo R. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation / R. Perrilo, J. Rakela, J. Deinstage et al. // Hepatology. – 1999. – Vol.29. – P. 1581–1586.; Hadziyannis S.J. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years / S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote et al. // Gastroenterology. – 2006. – Vol.131, №6. – P. 1743–1751.; Melegari M. Hepatitis B mutants associated with 3 TC and famciclovir administration are replication defective /M. Melegari, P.P. Scaglioni, J.R. Wands // Hepalology. – 1998. – Vol.27. – P. 628–633.; Hadziyannis S.J. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B / S.J. Hadziyannis, G.V. Papatheodoridis, E. Dimou et al. // Hepatology. – 2000. – Vol.32, №4, Pt.1. – P. 847–851.; Lin S.M. Interferon therapyin HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma / S.M. Lin, M.L. Yu, C.M. Lee et al. // J. Hepatol. – 2007. – Vol.46, №1. – P. 45–52.; Lampertico P. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy / P. Lampertico, E. Del Ninno, M. Vigan et al. // Hepatology. – 2003. – Vol.37, №4. – P. 756–763.; Moucari R. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up / R. Moucari, A. Korevaar, O. Lada et al. // J. Hepatol. – 2009. – Vol.50, №6. – P. 1084– 1092.; Fattovich G. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) / G. Fattovich, G. Giustina, J. Sanchez- Tapias et al. // Am J. Gastroenterol. – 1998. – Vol.93, №6. – P. 896–900.; Lau G.K. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B / G.K. Lau, T. Piratvisuth, K.X. Luo et al. // N. Engl. J. Med. – 2005. – Vol.352, №26. – P. 2682–2695.; Janssen H.L. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / H.L. Janssen, M. van Zonneveld, H. Senturk et al. // Lancet. – 2005. – Vol.365, №9454. – P. 123–129.; Chan H.L. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone / H.L. Chan, N.W. Leung, A.Y. Hui et al. // Ann Intern Med. – 2005. – Vol.142, №4. – P. 240–250.; Marcellin P. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B / P. Marcellin, G.K. Lau, F. Bonino et al. // N. Engl. J. Med. – 2004. – Sep.; Buster E.H. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b / E.H. Buster, H.J. Flink, Y. Cakaloglu et al. // Gastroenterology. – 2008. – Vol.135, №2. – P. 459–467.; Marcellin P. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a / P. Marcellin, F. Bonino, G.K. Lau et al. // Gastroenterology. – 2009. – Vol.136, №7. – P. 2169– 2179. – e.1–4.; Buster E.H. Factors that Predict Response of Patients with Hepatitis Be Antigen-Positive Chronic Hepatitis B to Peginterferon-alpha / E.H. Buster, B.E. Hansen, G.K. Lau et al. // Gastroenterology. – 2009. – Sep. 5. В печати.; Нурмухаметова Е.А. Генотипы вируса гепатита В: потенциальное клиническое значение / Е.А. Нурмухаметова, Н.П. Блохина // Фарматека. – 2008. – Т.156, №2. – С.33–35.; EASL Clinical Practice Guidelines: managment of chronic hepatitis B. European Association For The Study Of The Liver // J. Hepatol. – 2009. – Vol. 50, №2. – P. 227–242.; Brunetto M.R. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAgnegative chronic hepatitis B / M.R. Brunetto, F. Moriconi, F. Bonino et al. // J. Gepatol. – 2009. – Vol.49, №4. – P. 1141–1150.; Moucari R. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa- 2a in HBeAg-negative patients / R. Moucari, V. Mackiewicz, O. Lada et al. // Hepatology. – 2009. – Vol.49, №4. – P. 1151–1157. PEGASYS and its association with post-treatment response in HBeAg positive chronic hepatitis B.; GKK Lau // Presented at: Asian Pacific Association for the Study of the Liver (APASL). –Poster 083. – February 13–16, 2009; Hong Kong, China.; Chang T.T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B; BEHoLD; AI463022 Study Group / T.T. Chang, R.G. Gish, R. de Man et al. // N. Engl. J. Med. – 2006. – Vol.354, №10. – P. 1001– 1010.; Lai C.L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B; BEHoLD AI463027 Study Group / C.L. Lai, D. Shouval, A.S. Lok et al. // N. Engl. J. Med. – 2006. – Vol. 354, №10. – P. 1011–1020.; Gish R.G. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / R.G. Gish //Gastroenterology. – 2007. – Vol.133. – P. 1437–1444.; Lai C.L. Telbivudine versus lamivudine in patients with chronic hepatitis B / C.L. Lai, E. Gane, Y.F. Liaw et al. // N. Engl. J. Med. – 2007. – Vol.357. – P. 2576–88.; Liaw Y.F. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B; GLOBE Study Group / Y.F. Liaw, E. Gane, N. Leung et al. // J. Gastroenterol. – 2009. – Vol.136, №2. – P. 486–495.; Zeuzem S. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / S. Zeuzem, E. Gane, Y.F. Liaw et al. // J. Hepatol. – 2009. – Vol.51, №1. – P. 11–20.; Keeffe E.B. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update / E.B. Keeffe, D.T. Dieterich, S.H. Han et al. // Clin. Gastroenterol. Hepatol. – 2008. – Vol.6, №12. – P. 1315– 1341.; Marcellin P. Tenofovir dixoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B / P. Marcellin, E.J. Heathcote, M. Buti et al. // N. Engl. J. Med. – 2008. – Vol.359, №23. – P. 2442–2455.; Rajendra A. Economics of chronic hepatitis B and hepatitis C / A. Rajendra, J.B. Wong // J . Hepatol. – 2007. –Vol.47, №4. – P. 608–617.; Takkenberg B. Baseline HBsAg level predict HBsAg loss in chronic hepatitis B patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysi / B. Takkenberg, H. Zaaijer, C. Weegink et al. // J. Hepatol. – 2009. – Vol 50 (Suppl 1) . – P. S8.; Rizzetto M. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon / M. Rizzetto, F. Rosina, G. Saracco et al. // J. Hepatol. – 1986. – Vol.3. – Suppl.2. – P. 229–233.; Rosina F. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study / F. Rosina, C. Pintus, C. Meschievitz et al. // Hepatology. – 1991. – Vol.13, №6. – P. 1052–1056.; Farci P. Treatment of chronic hepatitis D with interferon alfa-2a / P. Farci, A. Mandas, A. Coiana et al. //N.Engl.J.Med.– 1994. – Vol.330, №2. – P. 88–94.; Gaudin G.L. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial / G.L. Gaudin, P. Faure, H. Godinot et al. // Liver – 1995. – Vol.15, №1. – P. 45–52.; Castelnau C. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up / C. Castelnau, F. Le Gal, M.P. Ripault et al. // J. Hepatol. – 2006. – Vol.44, №3. – P. 728–735.; Niro G.A. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta / G.A. Niro, A. Ciancio, G.B. Gaeta et al. //Hepatology. – 2006. – Vol.44, №3. – P. 713–720.; Heidrich B. Virological and clinical characteristics of delta hepatitis in Central Europe / B. Heidrich, K. Deterding, H.L.Tillmann et al. // J. Viral Hepat. – 2009. – № 12. – P. 883–94.; Yurdaydin C. Hepatitis D. / C. Yurdaydin, E.S. Koytak, J.S. Glenn // Curr Treat Options Gastroenterol. – 2007. – Vol.10, №6. – P. 456–463.; Балаян М.С. Вирусные гепатиты. Энциклопедический словарь. – 2-е изд. / М. С. Балаян, М. И. Михайлов. – М., 1999. – 42 с.; Weisberg I. New Treatments for Hepatitis C: Life Cycle Lessions / I. Weisberg, S.H. Sigal, I.M. Jacobson //Current Hepatitis Reports. – 2007. – Vol.6. – P. 75–82.; Marcellin P. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects / P. Marcellin, M.A. Loriot, N. Boyer et al. // Hepatology. – 1990. – Vol.12, №1. – P. 155–158.; Tripi S. Interferon-alpha alone versus Interferonalpha plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-alpha Treatment / S. Tripi, G. Di Gaetano, M. Soresi et al. // BioDrugs. – 2000. – Vol.13, №4. – P. 299–304.; Barbaro G. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study / G. Barbaro, G. Di Lorenzo, M. Soldini et al. // Am J. Gastroenterol. – 1998. – Vol.93, №12. – P. 2445–2451.; Clarysse C. Genotype, serum level of HCV-RNA and response to interferon-alpha treatment in patients with chronic hepatitis C / C. Clarysse, C. Van den Eynde, F. Nevens et al. // Neth. J. Med. – 1995. – Vol.47, №6. – P. 265–271.; Lee S.S. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values/ S.S. Lee, M. Sherman // J Viral Hepat. – 2001. – Vol. 8, №3. – Р. 202–205.; Saracco G. The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review / G. Saracco, M. Rizzetto // J. Gastroenterol., Hepatol. – 1995. – Vol.10, №6. – P. 668–673.; Manns M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial / M.P. Manns, J.G. McHutchison, S.C. Gordon et al. // Lancet. – 2001. – Vol.358, №9286. – P. 958–965.; Hadziyannis S.J. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose; PEGASYS International Study Group / S.J. Hadziyannis, H. Jr. Sette, T.R. Morgan et al. // Ann Intern Med. – 2004. – Vol.140, №5. – P. 346–355.; Лобзин Ю.В. Вирусные гепатиты: клиника, диагностика, лечение / Ю.В. Лобзин, К.В. Жданов, В.М. Волжанин, Д.А. Гусев. – Санкт-Петербург: Фолиант. – 2006. – 184 с.; Marcellin P. Improved Prediction of SVR by Differentiating Early Virologic Response (EVR) into Rapid Virologic Response (RVR), Complete EVR (cEVR) and Partial EVR (pEVR) in Genotype 1 Patients Treated ith Peginterferon Alfa- 2a (40KD) Pegasys ) and Ribavirin (Copegus ) / P. Marcellin, D. Jensen, S. J. Hadziyannis et al. // Hepatology International. – Vol.2, Supplement 3, №3 – 2008. – Abstract FP022. – P. 332.; Jensen D.M. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy / D.M. Jensen, T.R. Morgan , P. Marcellin et al. // J. Hepatol. – 2006. – Vol.43, №5. – P. 954–60.; Zeuzem S. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia / S .Zeuzem, M. Buti, P. Ferenci et al. // J. Hepatol. – 2006. – Vol.44, №1. – P. 97–103.; Fried M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried, M.L. hiffman, K.R. Reddy et al. // N. Engl. J. Med.– 2002. – Vol.347, №13. – P. 975–982.; Ferenci P. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin / P. Ferenci, M.W. Fried, M.L. Shiffman et al. // J. Hepatol. – 2005. – Vol.43, №3. – P. 425–433.; Berg T. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin / T. Berg, M. von Wagner, S. Nasser et al. // J. Gastroenterol. – 2006. – Vol.130, №4. – P. 1086–1097.; Sanchez – Tapias J.M. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment / J.M. Sanchez – Tapias, M. Diago, P. Escartín, J. Enríquez et al. //J. Gastroenterol. – 2006. – Vol.130, №4. – 1086–1097.; Bronowicki J.P. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin / J.P. Bronowicki, D. Ouzan, T.Asselah et al. // J. Gastroenterol. – 2006. – Vol.131, №4. – P. 1040- 1048.; Pearlman B.L. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders / B.L. Pearlman, C. Ehleben, S. Saifee // J. Hepatol. – 2007. – Vol.46, №6. – 1688–1694.; Fried M.W., Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection / M.W. Fried // Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. – J. Hepatol. – April 2008.; Dalgard O. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response / O. Dalgard, K. Bjøro, H. Ring-Larsen et al. // J. Hepatol. – 2008. – Vol.47, №1. – P. 35–42.; Shiffman M.L. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3; ACCELERATE Investigators / M.L. Shiffman, F. Suter, B.R. Bacon et al. // N. Engl. J. Med. – 2007. – Vol.357, №2. – P. 124–134.; Willems B. 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study / B. Willems // Program and abstracts of the 42nd Meeting of the EuropeanAssociation for the Study of Liver Diseases. – J. Hepatol. – April 2007.; Fried M.W. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin / M.W. Fried, D.M. Jensen, M. Rodriguez-Torres et al. // J. Hepatol. – 2008. – Vol.48, №4. – P.1033–1043.; Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM1) (SPRINT-2). In print // www.clinicaltrials. gov/ct2/show/NCT00705432?term=SPRINT-2&rank=1.; Zeuzem S. Telaprevir in combination with peginterferon –alfa-2а with or without ribavirin in the treatment of chronic hepatitis C: final results of the prove2 / S. Zeuzem, C. Hezode, P. Ferenci et al. // Abstract 243. – J. Hepatol. – 2008. – Vol.48, №4 (suppl). – P. 113 A.; Gane E.G. Antiviral activity of the HCV nucleocide polymerase inhibitor R7128 in HCV genotype 2 and 3 prior nonresponders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days / E.G. Gane, M. Rodriguez-Torres, D.R. Nelson et al. // J. Hepatol., Abstract LB10. – 2008. – Vol.48, №4 (suppl). – P. 267 A.; Maylin S. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C / S. Maylin, M. Martinot-Peignoux, R. Moucari et al. // J. Gastroenterol. – 2008. – Vol.135, №3. – P. 821–829.; https://journal.niidi.ru/jofin/article/view/270
-
7Academic Journal
المؤلفون: Кожанова, Т., Ильченко, Л., Исаева, О., Алексеева, М., Сарыглар, А., Миронова, Н., Громова, Н., Цыкина, М., Зубков, Ю., Кюрегян, К., Михайлов, М.
وصف الملف: text/html
-
8
المصدر: Инфекция и иммунитет.
وصف الملف: text/html
-
9
المصدر: Современные технологии в медицине.
وصف الملف: text/html
